Skip to main content
ZVRA
NASDAQ Life Sciences

Zevra Q3 Revenue Jumps 45% to $37.8M as MIPLYFFA Hits $34M; Swings to $19.2M Profit

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$10.26
Mkt Cap
$609.278M
52W Low
$8.01
52W High
$15.035
52W Position info
28% above low
Off High info
32% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

ZVRA sits 28% above its 52-week low of $8.01.

Summary

Zevra posted Q3 2026 net revenue of $37.8 million, up 45% from $26.1 million a year ago, with $34.0 million of that coming from MIPLYFFA. The company swung to net income of $19.2 million, or $0.31 per basic share, versus a small loss a year earlier, helped by a $5.1 million noncash gain on warrant and CVR fair value adjustments. Cash, equivalents and investments stood at $270.9 million at September 30, and management says that funds the current operating plan. Commercial momentum is steady but not accelerating sharply: 13 new MIPLYFFA prescription enrollment forms in the quarter brought the total to 197 since launch, and 134 patients are enrolled in the global Expanded Access Program. The open items are regulatory — Zevra has requested re-examination of its EU marketing application for arimoclomol and is awaiting the outcome, and it plans to file a supplemental NDA for MIPLYFFA in infants under 24 months in Q1 2027. On celiprolol, the Phase 3 DiSCOVER trial has 72 patients enrolled with four confirmed events, and the company has held an FDA Type C meeting on submission strategy. The 4:30 p.m. ET call today is where guidance and the EU timeline will get pressed.

At the time of this announcement, ZVRA was trading at $10.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $609.3M. The 52-week trading range was $8.01 to $15.04. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ZVRA - Latest Insights

ZVRA
Nov 13, 2026, 6:26 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $10.10
Real-time Price: $9.06 info
Change: -$1.04 (-10%) info
Market Cap: $539.707M info
ZVRA
Nov 03, 2026, 5:16 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $10.50
Real-time Price: $9.06 info
Change: -$1.44 (-14%) info
Market Cap: $539.707M info
ZVRA
Aug 05, 2026, 5:19 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.50
Real-time Price: $9.06 info
Change: -$1.44 (-14%) info
Market Cap: $539.707M info
ZVRA
Aug 05, 2026, 5:10 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $10.60
Real-time Price: $9.06 info
Change: -$1.54 (-15%) info
Market Cap: $539.707M info
ZVRA
Jun 23, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $12.42
Real-time Price: $9.06 info
Change: -$3.36 (-27%) info
Market Cap: $539.707M info